Lp(a) Packs a More Powerful Atherogenic Punch Than LDL
Lp(a) is associated with higher atherogenic risk than LDL on a per-particle basis, providing a rationale for potentially targeting elevated levels, researchers said.
Stay updated with breaking news from Vera Bittner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lp(a) is associated with higher atherogenic risk than LDL on a per-particle basis, providing a rationale for potentially targeting elevated levels, researchers said.
A UK Biobank analysis confirms that LDL is more abundant and drives most ASCVD risk, but Lp(a) carries a powerful punch.
The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.
Lp(a), called the holy grail of prevention research, was reduced dramatically with SLN360 and should spur further research.
Whether such an individualized approach is feasible in a larger study or cost-effective in the real world remains unclear.